reason report
continu thru year
bottom line remain outperform given view
life scienc tool lst leader unmatch
scale reach research lab market combin
number growth product serv key end-market grow
consolid posit deliv impress y/i growth
quarter despit tough comp broad-bas beat end-
market pharma strength notabl low-teen growth
y/i industrial-appli mid-singl digit msd academic/gov
diagnost dx market believ uniqu lever growth
biolog biomolecular drug multipl point discoveri
product broad growth profil portfolio continu deliv
across board though see stronger y/i growth comp
still believ abl deliv in-lin msd
growth outlook rais pt
strong growth broad base across major end-market
continu year key segment includ
lab product servic lp contribut strength
 averag org across key segment despit
solid comp given sheer size posit lst market
investor believ like pay closer attent tougher comp
emerg limit chang tariff believ
could deliv growth gener dri powder
avail execut deal drive growth accret
model lt continu put capit work repay debt reduc
leverag ratio year ago today
growth china still strong limit chang tariff
china end year reflect continu opportun
materi scienc biolog research believ investor
watch tariff close despit estimate impact --
plan off-set continu see growth china find
challeng replac high-end technolog includ chrom mass spec
fei electron microscop also divest anatom
patholog busi also reflect guid
guid suggest conserv outlook believ investor
still focu tougher comp believ conserv
guid strength past year exceed expect
guid org revenue ep
 estim reflect org revenue growth
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu ep exclud charg amort intang
pleas refer page import disclosur price chart analyst certif
rate thermo fisher scientif outperform price target
remain outperform-r given view compani life scienc tool
lst leader unmatch scale reach research lab market combin
number growth product serv key end-market also acquir view
consolid sizabl portion lst market patheon acquisit close
believ potenti consolid contract develop manufactur
organ industri long term view posit given sheer
scale reput presenc lst market biopharma academ channel
industrial/environment diagnost deliv manag forecast grow
solidifi presenc emerg market asia-pacif china revenu
continu strength biopharma end-market view sign slow
near term inorgan growth continu remain key prioriti next five
year capit deploy estim suggest debt/
share current trade ev/ebitda slightli large- mid-
cap tool averag ev/ebitda given
impress growth deliv leverag biolog drug discoveri develop
product china emerg market tailwind still continu believ hold
posit lead lab tool suppli provid like continu post strong growth
expect trade line large- mid-cap tool averag ev/ebitda
multipl deliv ev/ebitda result deriv price target appli
multipl ebitda estim
primari risk price target includ
slowdown global budget research could caus downsid risk forecast
tighten budget govern academ fund could result lower revenu
rel estim furthermor restrict global budget could result shift focu
strategi growth could increas oper risk declin government spend
could risk downsid forecast growth nih spend
biopharma declin pose greatest risk tmo revenu declin biopharma fund
could highli impact revenu given third revenu lever biopharma
industri slowdown biopharma fund would result downsid risk estim
valuat biomolecul forecast ramp drug market mid-teen
estim hing prolifer drive use tmo bioprocess
equip mass spectromet instrument reagent character
scale diversif could backfir tmo size diversif
advantag compani consolid space pose signific challeng term
move needl growth perspect given size acquisit
alreadi done includ life pthn transact would ventur estim
deal size least grow north organ make signific move
market although asset might visibl street given limit public
asset larg number privat asset could potenti avail howev
pose risk street might appreci capabl asset enough
move needl
emerg market pose signific risk tmo revenu geopolit risk
emerg market could disrupt oper downsid risk valuat forecast
risk could countri region specif could also impact tmo strategi creat
higher barrier entri exist futur market local product reagent prefer
import oper numer intern market includ india
china eastern europ name
tmo exposur china could also pose concentr risk china repres
tmo revenu macroeconom impact chines market could lead declin
compani revenu regul chines polici could also caus restrict oper
lead lower activ china question remain china relat
detail headwind could emerg polici risk
 synergi may go plan tmo acquisit sizabl may go
plan could result integr risk lower-than-expect synergi integr
requir cultur process adapt synergi model forecast
risk estim remain integr unquantifi aspect target
forecast model margin eros could occur under-perform
increas risk amazon distribut busi like impact revenu
tmo laboratori product servic lp busi custom shown
will consid amazon vendor consum product expir
date beaker pipett expect amazon expertis logist suppli chain
allow amazon offer product competit cost thu impact lp revenu overal
dollar million except per share data
good sold
net incom continu op
sg sale
 sale
oper expens sale
compani report leerink partner estim
